Posted by Geraldine @ MaRS, December 8th, 2009

Paul Martin speaks at Impact Investing
What happens when you put a former Liberal Prime Minister, a former Conservative Party Leader and a leading social impact investor in a room? Fireworks? Pouting and disagreement? Or one of the most electric and optimistic events I’ve been to this year.
On November 6, the Rt. Hon. Paul Martin and Social Capital Partners (SCP), Bill Young came to MaRS for an event called, “Impact Investing: Building Prosperity Outside the Mainstream,” moderated by John Tory and Ilse Treurnicht. The discussion focused on how market forces can be used effectively to solve social challenges in Canada.
Read More »
Posted by Ilse @ MaRS, November 19th, 2009

Aging: Our next big mission
Look around you and chances are you’ll notice that Canada’s population, along with the rest of the world, is aging rapidly. While this isn’t news for most of us, it’s certainly becoming a popular topic, with the first wave of the infamous Baby Boomers turning 65 next year. They say “time flies” but this generation’s flight time will result in a heavy impact.
Aging affects us all and the aging of our society presents a sobering challenge. Within the next 10 years, Canadians over the age of 65 will outnumber those under the age of 15. If the present yearly growth in life expectancy continues through the 21st century, most babies born after 2000 will celebrate their 100th birthdays.
Read More »
Posted by Crystal Cockerham, August 29th, 2008
The MaRS Transition team is taking to the park paths in the Diabetes Walk for Hope. We’re walking to help the Diabetes Hope Foundation encourage youth to pursue their academic dreams and other fulfilling activities. With your support, our team will help ensure future scientific and social innovators receive encouragement from the Diabetes Hope Foundation to handle the responsibility of living with diabetes and continue to reach for the stars.
For Transition, diabetes is a subject that is close to our hearts. The company has been pursuing disease modifying therapies for diabetes since 2002. This commitment to diabetes is as strong as ever as Transition and its development partner, Eli Lilly are performing phase 2 clinical development with its lead diabetes product, TT-223.
Read More »
Posted by Chris @ MaRS, June 24th, 2008
If the global nonprofit sector were a single industry, it would be the world’s fifth largest, employing 4.5% of the world’s population. This and many other dramatic insights were unveiled by Kim Klein in a recent presentation on Canada’s nonprofit sector at the Laidlaw Foundation.
The data, compiled from Imagine Canada, the National Survey of Nonprofit and Voluntary Organizations, Johns Hopkins University’s Center for Civil Society Studies and the Association of Fundraising Professionals, map the nonprofit sector’s size, composition, and finance structure, and offer international and inter-provincial comparisons.
Read More »